Transgene Biotek has been granted United State of America patent on technology for Oral delivery of Insulin and Insulin analogues.
This patent is a feather in the cap of Transgene Biotek’s list of global patents. This intimation of patent being granted by USA will strengthen the company’s management to justifiably increase its monetary value of its technology for oral delivery of Insulin and its analogues. With emergence of Insulin analogues across the globe from several large pharma companies, Transgene’s oral delivery technology shall provide a new dimension for such molecules to deliver them through a convenient and increased patient compliant oral route.
Transgene Biotek (TBL) is engaged in manufacturing drugs.